2010-09-06 16:28:14 -

Research and Markets ( www.researchandmarkets.com/research/fe4133/urological_disorde : ) has announced the addition of the " Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets : " report to their offering.

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets : . It provides in-depth analysis of the unmet needs, drivers and barriers that affect the global urological disorders therapeutics market. The report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and annual cost

of therapy are forecast until 2016 for key geographies in the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Global Urological Disorders Market


The authors indicate that the global urological disorders market has been one of the fastest growing markets in the pharmaceutical industry.

However, the market growth is expected to slow down in the future due to various restraints such as the expiry of key drugs patents across all disease segments, entry of generic, and decreased annual cost of therapy in major markets such as the US, Japan and the top five countries in Europe. Nevertheless, the global urological disorders market is still forecast to grow at a moderate rate in the future.

The Global Urological Disorders Market is Forecast to Show Moderate Growth


In 2009, the global urological disorders market was estimated to be worth $7.9 billion, representing a cumulative annual growth rate (CAGR) of 9.6% between 2001 and 2009. The market is forecast to reach $9.8 billion by 2016, indicating a CAGR of 3.1% between 2009 and 2016. The primary reason for the reduced growth rate is the patent expiries of major blockbusters, which subsequently is expected to decline the annual cost of therapy after 2009.

The global urological disorders market is expected to witness a series of patent expiries between 2009 and 2016, which includes most of the top selling blockbuster drugs in the Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI) market.

The major drugs that are set to lose patent protection include Flomax (2009), Levaquin (2010), Uroxatral - in US (2011), Detrol (2012), Avodart (2015), Enablex (2015) and Ditropan XL (2015). All these drugs together account for more than $6.3 billion of revenues in the global urological disorders market.

The current urological disorders pipeline does offer some promising novel products. However, the revenues generated from these products are not expected to completely make up for the revenues lost due to patent expiries. Thus, the overall market growth of the global urological disorders market is expected to decline during the forecast period.

Scope



- Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.


- Analysis of the leading therapeutic segments, including Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI).


- Analysis of the urological disorders market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.


- Market characterization of the urological disorders market, including market size, annual cost of therapy and treatment usage patterns.


- Key drivers and barriers that have a significant impact on the market.


- Coverage of pipeline molecules in various phases of drug development.


- Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and Johnson and Protox Therapeutics, Inc.


- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global urological disorders market.

Reasons to buy



- Align your product portfolio to the markets with high growth potential.


- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.


- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.


- Develop key strategic initiatives by understanding the key focus areas of leading companies.


- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.



Key Topics Covered:

- Global Urological Disorders Market: Introduction
- Global Urological Disorders Market: Market Overview
- Global Urological Disorders Market: Therapeutic Landscape
- Global Urological Disorders Market: Geographical Landscape
- Global Urological Disorders Market: Pipeline Analysis
- Global Urological Disorders Market: Competitive Landscape
- Global Urological Disorders Market: Strategic Consolidations
- Global Urological Disorders Market: Appendix

Companies Mentioned.

- Astellas Pharma
- Johnson and Johnson (J&J)
- Pfizer
- GlaxoSmithKilne (GSK)
- Sanofi-Aventis


For more information visit www.researchandmarkets.com/research/fe4133/urological_disorde :



Research and MarketsLaura Wood, Senior Manager, press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.

Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716